CorMedix Soars on Blowout Quarter, Raises 2026 Financial Guidance

PARSIPPANY, N.J. – May 14, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today delivered a powerful message to investors, reporting first-quarter financial results that significantly surpassed expectations and prompted an upward revision of its full-year guidance. The biopharmaceutical company announced a staggering 226% year-over-year revenue increase, reaching $127.4 million for the quarter, driven by the robust performance of its flagship product, DefenCath®, and substantial contributions from its recently acquired Melinta portfolio.

The impressive top-line growth translated directly to the bottom line, with CorMedix posting a net income of $38.6 million, or $0.43 per diluted share. The company's adjusted EBITDA, a key measure of operational profitability, reached $70.0 million, a nearly 200% increase from the same period last year. This strong start to 2026 has emboldened management to raise its full-year revenue forecast to a range of $325 to $345 million and its adjusted EBITDA guidance to between $115 and $135 million, signaling sustained confidence in its commercial execution and growth trajectory.

Unpacking the Financial Surge

A closer look at the first-quarter results reveals a multi-faceted growth story. The primary engine remains DefenCath (taurolidine and heparin), a catheter lock solution designed to prevent bloodstream infections in hemodialysis patients. The product generated $97.5 million in net revenue, benefiting from what the company described as strong underlying demand and increased use among outpatient dialysis customers. This performance was further aided by the full-quarter impact of onboarding a large dialysis organization in mid-2025.

Notably, the quarter's DefenCath sales included a non-recurring $9.0 million favorable change in estimate related to sales allowances. While this one-time adjustment boosted the quarterly figures, the underlying growth trend remains a key indicator of the product's market penetration.

The second pillar of CorMedix's revenue growth is the strategic acquisition of Melinta Therapeutics, completed in August 2025. The acquired portfolio of anti-infective products contributed $29.9 million in the first quarter, demonstrating the immediate financial impact of the deal. This strategic expansion has diversified CorMedix's revenue base and allowed it to leverage its existing commercial infrastructure in hospitals and clinics. However, this growth has come with increased investment. Total operating expenses climbed to $41.5 million from $17.4 million in the prior-year quarter, reflecting the costs of integrating Melinta and scaling up marketing, administrative, and R&D functions to support the larger, combined entity.

Navigating DefenCath's Future Market

While DefenCath's current success is undeniable, CorMedix faces a pivotal shift in the product's reimbursement landscape. CEO Joseph Todisco acknowledged this in his commentary, noting that DefenCath continues to exceed expectations "despite pending TDAPA expiration." This refers to the Transitional Drug Add-on Payment Adjustment (TDAPA), a Medicare program that provides a separate, additional payment for new and innovative products used in dialysis settings.

The expiration of TDAPA means DefenCath's reimbursement will eventually be bundled into the standard End-Stage Renal Disease (ESRD) payment rate. This shift typically increases pricing pressure and requires manufacturers to rigorously demonstrate their product's cost-effectiveness to maintain market share. CorMedix's ability to secure strong utilization from large dialysis organizations ahead of this change is a critical part of its strategy to navigate this transition. The company's proactive approach and the product's established clinical value in preventing costly bloodstream infections will be crucial in defending its market position once the add-on payment is removed.

Building for Tomorrow: A Pipeline of Critical Care Innovations

Beyond its impressive commercial performance, CorMedix is making significant strides in advancing its clinical pipeline, positioning the company for long-term, sustainable growth. The most significant recent development is the positive Phase III topline data from the global ReSPECT trial for REZZAYO® (rezafungin for injection).

The trial evaluated the drug as a prophylaxis to prevent invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation—a highly vulnerable population with a critical unmet medical need. Positive results in a late-stage trial represent a major de-risking event for the asset. CorMedix, in collaboration with its global partner, is now preparing to submit a supplemental New Drug Application (sNDA) to the FDA in the second half of 2026. A potential commercial launch for this new indication is targeted for 2027, which would open a new and significant revenue stream for the company.

Simultaneously, CorMedix continues to invest in expanding the use of its core taurolidine-based technology. A Phase 3 study is currently enrolling patients to evaluate the taurolidine/heparin catheter lock solution for use in patients receiving Total Parenteral Nutrition (TPN). Recognizing that the trial is trending toward a 2028 completion, the company is actively taking steps to accelerate enrollment. These measures include opening new study sites and submitting a protocol amendment to the FDA, which, if approved, would broaden patient eligibility by removing certain exclusion criteria. This demonstrates a commitment to maximizing the value of its core technology across different patient populations with high infection risks.

Joseph Todisco, CorMedix Chairman & CEO, summarized the company's position: “CorMedix has entered 2026 with strong momentum across all areas of our business. In addition, we are advancing a pipeline of late-stage opportunities, including REZZAYO for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity. Lastly, we have delivered significant profitability and cash generation, allowing us to reinvest in growth, as well as shareholder value creation through stock repurchases, while preserving financial flexibility for new business development initiatives."